GIST Clinical Trial
— AVIATOR2020Official title:
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients : AVapritinib Real-life observatTORy
Verified date | December 2023 |
Source | Centre Leon Berard |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
GIST are rare mesenchymal tumors of the gastrointestinal tract characterized by somatic mutations in the gene encoding the KIT (85%) or the PDGFRα (8%) protein. Treatment of localized forms relies on adequate surgery without tumor spillage and sometimes systemic treatment with imatinib according to risk of relapse defined by localization, tumor size and mitotic count, as well as mutational status. More than 40% of cases may recur and metastasize. Advanced and relapsing forms are currently treated with oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR such as imatinib (standard treatment), sunitinib (2nd line) and regorafenib (3rd line). Nevertheless, imatinib has little or no activity in patients harboring the D842V mutation in the exon 18 of PDGFRα (20% of gastric GIST, 6% of all GIST patients). Consequently, other therapeutic alternatives are needed. Results from the phase I single-arm NAVIGATOR study show that avapritinib has significant efficacy in GIST patients with PDGFRα D842V mutation (ORR = 86 %). In France, an authorization for temporary use (ATUc) starting on September 21st, 2020 has been granted by the National Agency for Safety of Medicines and Health Products (ANSM). It allows the early availability of avapritinib in France while waiting for Market Authorization Approval (AMM). This ATUc is now being followed by a post-ATU period. The objective of this real-life registry is to perform a long-term longitudinal follow up of PDGFRA D842V-mutated GIST patients and to collect effectiveness and safety data. It will be implemented in parallel to the post-ATUc period until June 2023. Moreover, this registry fulfills the HAS's ("Haute Autorité de Santé") request regarding the Establishment of an exhaustive registry of patients with GIST, harboring the D842V / PDGFRA mutation in France. This registry will specifically describe: - patient characteristics, in particular patient age, of the disease characteristics, previous treatments; - the clinical course; - the occurrence of adverse events / effects; - and the therapeutic strategy (endpoint of treatment or continuation). Data from the electronic health record (EHR) will be collected. Moreover, as per the ANSM's requirements, quality of life and cognitive function will be investigated using FACT-G, FACT-Cog and MoCA questionnaires. Undesirable effects will be collected as well. Follow-up is envisioned for a minimum of 2 years.
Status | Active, not recruiting |
Enrollment | 25 |
Est. completion date | December 31, 2024 |
Est. primary completion date | April 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - I1. Adult (=18 years old), male or female - I2. Patient with a histologically or cytologically-confirmed diagnosis of unresectable or metastatic GIST harboring the D842V mutation in the PDGFRa gene - I3. . Diagnosis date later than Jan 1st 2010 - I4. Non opposition to the use of her/his data Exclusion criteria : - E1. Patient not meeting all the inclusion criteria |
Country | Name | City | State |
---|---|---|---|
France | CHRU Besançon | Besançon | |
France | Insitut Bergonié | Bordeaux | |
France | CHU Clermont Ferrand | Clermont-Ferrand | |
France | Centre Léon Bérard | Lyon | |
France | Institut de Cancérologie de l'Ouest (ICO) | Nantes | |
France | CHU Robert Debré | Reims | |
France | Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Centre Leon Berard | Blueprint Medicines Corporation |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival | survival of patients treated with Avapritinib in real life according to overall survival. | up to 48 months | |
Secondary | Progression Free Survival | according to RECIST criteria | after 12, 24 and 36 months | |
Secondary | Incidence of long-term responders | (>24 months) | up to 48 months | |
Secondary | Duration of treatment | duration in months | up to 48 months | |
Secondary | Safety: Nature of AEs | AEs graded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | up to 48 months | |
Secondary | Safety : Frequency of AEs | AEs graded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | up to 48 months | |
Secondary | Safety : Severity of AEs | AEs graded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | up to 48 months | |
Secondary | Cognitive impairment in real-life according to MoCA questionnaires | Montreal Cognitive Assessment (MoCA) | Day 1, Day 15, Month 2, Month 3, Month 6, Month 12, Month 18, Month 24, Month 36 | |
Secondary | Cognitive impairment in real-life according to FACT-Cog | Functional Assessment of Cancer Therapy - Cognitive Function | Day 1, Day 15, Month 2, Month 3, Month 6, Month 12, Month 18, Month 24, Month 36 | |
Secondary | Quality of life in real-life according to FACT-G questionnaire | Functional Assessment of Cancer Therapy - General | Day 1, Day 15, Month 2, Month 3, Month 6, Month 12, Month 18, Month 24, Month 36 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05957367 -
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
Active, not recruiting |
NCT03556384 -
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Recruiting |
NCT05895942 -
Exploring the Molecular Mechanism Based on KIT Mutation
|
||
Completed |
NCT01459757 -
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
|
N/A | |
Completed |
NCT00979381 -
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
|
N/A | |
Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Completed |
NCT04599660 -
Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
|
||
Completed |
NCT05400018 -
Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
|
||
Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04825470 -
Liver Transplantation for Unresectable GIST Liver Metastases
|
N/A | |
Recruiting |
NCT00687778 -
11C-Acetate PET/CT Non-FDG-Avid Tumors
|
N/A | |
Completed |
NCT00979329 -
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
|
N/A | |
Completed |
NCT03465722 -
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
|
Phase 3 | |
Completed |
NCT03880617 -
Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Completed |
NCT01323400 -
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
|
Phase 2 | |
Recruiting |
NCT05804331 -
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
|
||
Completed |
NCT01874665 -
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
|
Phase 2 |